Cancer Therapy News and Research

RSS

CPRIT awarded $142M in grants to fund cancer research and prevention programs across the state

The Cancer Prevention and Research Institute of Texas today awarded $142 million in grants to fund innovative cancer research and prevention programs across the state. Today's announcement caps the first year of the Institute's ten year mission. Together with matching funds committed by grant recipients, more than $300 million has been invested this year in Texas' extraordinary endeavor to change the face of cancer.

19 Jun 2010

National Cheng Kung University Hospital's Outpatient Building inaugurated

The Outpatient Building of National Cheng Kung University Hospital was officially inaugurated on June 12th to provide excellent medical service and to further ensure the health of people in Southern Taiwan.

18 Jun 2010

Baylor University researchers awarded grant to research and test new compounds for cancer

The National Institutes of Health has awarded two Baylor University researchers a $1.46 million grant to research and test new compounds that could help fight cancerous tumors.

18 Jun 2010

Early detection helps prevent nearly thousand deaths from breast cancer each year: Research

NEARLY a thousand deaths from breast cancer could be avoided each year if short term survival rates in England were among the best comparable countries in Europe, according to research presented at the National Cancer Intelligence Network conference today.

17 Jun 2010

Bayer, OncoMed collaborate to develop anti-cancer stem cell therapeutics to target Wnt signaling pathway

Bayer Schering Pharma AG and OncoMed Pharmaceuticals, Inc., today announced a global strategic alliance to discover, develop and commercialize novel anti-cancer stem cell therapeutics targeting the Wnt signaling pathway.

17 Jun 2010

OncoMed, Bayer Schering Pharma to develop and commercialize novel anti-cancer stem cell therapeutics

OncoMed Pharmaceuticals, Inc. and Bayer Schering Pharma AG, Germany, today announced a global strategic alliance to discover, develop and commercialize novel anti-cancer stem cell therapeutics targeting the Wnt signaling pathway. Cancer stem cells are a subset of tumor cells believed to play a significant role in the establishment, metastasis and recurrence of cancer.

17 Jun 2010

“Experiment” with homeopathy killed a cancer patient: Inquest

Doctor Peter Dingle at an inquest into the events that led to the death of his wife Penelope, 45 on 25th August 2005 revealed that he had argued with her decision to go for alternative therapies as her colorectal cancer treatment.

17 Jun 2010

Curis reports topline results from GDC-0449 Phase II clinical trial for metastatic colorectal cancer

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced topline results from a Phase II clinical trial conducted by Roche and Genentech, Curis' collaborator and a wholly owned member of the Roche Group, of GDC-0449, a first-in-class Hedgehog pathway inhibitor. GDC-0449 was tested in combination with Avastin® (bevacizumab) and FOLFOX or FOLFIRI chemotherapy in first-line metastatic colorectal cancer patients.

17 Jun 2010

OXiGENE completes enrollment in ZYBRESTAT Phase 2 FALCON trial for NSCLC

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that it has completed its targeted enrollment of 60 patients in the FALCON trial, a randomized, controlled Phase 2 study of ZYBRESTAT™ in patients with non-squamous non-small cell lung cancer (NSCLC).

16 Jun 2010

Florida Advisory Council on Radiation Protection endorses ASTRO's Target Safely patient protection plan

Through a unanimous decision, the Florida Advisory Council on Radiation Protection has endorsed Target Safely, the American Society for Radiation Oncology's (ASTRO) patient protection plan.

16 Jun 2010

New combination appears to be effective against cancer stem cells in pancreatic cancer

The new cancer medication sorafenib looks promising. Sorafenib is used for advanced liver and kidney cancer and also appears to be effective against cancer stem cells in pancreatic cancer. The team led by Professor Dr. Ingrid Herr, Head of the Department of Molecular Oncosurgery, a group of the Department of Surgery at Heidelberg University Hospital, (Managing Director: Professor Dr. Markus W. B-chler) in cooperation with the German Cancer Research Center, tested the new substance in mice and pancreatic cancer cells.

16 Jun 2010

Galera Therapeutics completes Series 1 financing

Galera Therapeutics, a drug development company focused on novel therapeutics to protect against the side effects and increase the effectiveness of cancer treatment, today announced it has completed a Series 1 financing led by BioGenerator. Also participating in the round is Galera Angels, LLC, an angel investment group, and Analytical Bio-Chemistry Laboratories, Inc., of Columbia Missouri.

16 Jun 2010

Researchers examine rates of cancer in British white and British Indian population

British Indians have fewer cases of many different cancers including breast, prostate, colon and lung than the British white population, according to new research published in the British Journal of Cancer1 today (Wednesday).

16 Jun 2010

Sulindac shuts down cancer cell growth, initiates cell death: Study

Without knowing exactly why, scientists have long observed that people who regularly take non-steroidal anti-inflammatory drugs like aspirin have lower incidences of certain types of cancer. Now, in a study appearing in Cancer Cell on June 15, investigators at Sanford-Burnham Medical Research Institute and their colleagues have figured out how one NSAID, called Sulindac, inhibits tumor growth.

15 Jun 2010

ExonHit Therapeutics, Genmab A/S sign agreement for selection of novel splice variants

ExonHit Therapeutics today announced the signing of an exclusive agreement with Genmab A/S for a selection of novel splice variants, identified as part of a successful pilot study, that have the potential to be therapeutic targets for breast cancer. Genmab retains exclusive development and commercialization rights on 10 events out of a breast cancer database developed using ExonHit's genome-wide SpliceArray technology (RNA splicing analysis platform covering the entire genome).

15 Jun 2010

Medical marijuana advocates bypassing traditional approval, effectiveness regulations

NPR continues its examination of medical marijuana: "Fourteen states and the District of Columbia have launched a medical experiment that doesn't follow any of the rules of science. By approving the use of marijuana as a medicine — with varying kinds of restrictions — these jurisdictions are bypassing the federal government's elaborate processes for approving medicines."

14 Jun 2010

Report highlights deprivation gap caused by late diagnosis of cancer, differences in treatment choices

There could be as many as 14,000 fewer cases of cancer each year in England if everyone was as healthy as the richest 20 per cent in the country. And the difference between the classes is more marked among men than women. Among men there were 21 per cent more cases of cancer in the most deprived areas compared to the least deprived, whereas the gap among women was 11 per cent.

14 Jun 2010

Eribulin mesylate drug may help extend lives of women with advanced breast cancer

A new drug, based on a natural extract from sea sponge, may help to extend the lives of women with advanced breast cancer, UK scientists have found. A research team at the University of Leeds and St James's Institute of Oncology led an international trial of the new chemotherapy drug, eribulin mesylate.

11 Jun 2010

Widely used cancer drug bevacizumab can lead to proteinuria, kidney damage: Study

The widely used cancer drug bevacizumab may cause severe loss of protein from the kidney into the urine that can lead to significant kidney damage and can compromise the efficacy of cancer treatment, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology. The results suggest that physicians should monitor patients' kidney health when prescribing this angiogenesis inhibitor.

11 Jun 2010

UAB researchers win grant to study metastasis of dead cancer cells

Researchers with the University of Alabama at Birmingham (UAB) Comprehensive Cancer Center and UAB Department of Chemistry have won an $805,000 grant from the U.S. Department of Defense Breast Cancer Research Program to study whether dead cancer cells left over after treatment encourage cancer's spread to other parts of the body.

11 Jun 2010

Cancer Therapy News and Research

CPRIT awarded $142M in grants to fund cancer research and prevention programs across the state

National Cheng Kung University Hospital's Outpatient Building inaugurated

Baylor University researchers awarded grant to research and test new compounds for cancer

Early detection helps prevent nearly thousand deaths from breast cancer each year: Research

Bayer, OncoMed collaborate to develop anti-cancer stem cell therapeutics to target Wnt signaling pathway

OncoMed, Bayer Schering Pharma to develop and commercialize novel anti-cancer stem cell therapeutics

“Experiment” with homeopathy killed a cancer patient: Inquest

Curis reports topline results from GDC-0449 Phase II clinical trial for metastatic colorectal cancer

OXiGENE completes enrollment in ZYBRESTAT Phase 2 FALCON trial for NSCLC

Florida Advisory Council on Radiation Protection endorses ASTRO's Target Safely patient protection plan

New combination appears to be effective against cancer stem cells in pancreatic cancer

Galera Therapeutics completes Series 1 financing

Researchers examine rates of cancer in British white and British Indian population

Sulindac shuts down cancer cell growth, initiates cell death: Study

ExonHit Therapeutics, Genmab A/S sign agreement for selection of novel splice variants

Medical marijuana advocates bypassing traditional approval, effectiveness regulations

Report highlights deprivation gap caused by late diagnosis of cancer, differences in treatment choices

Eribulin mesylate drug may help extend lives of women with advanced breast cancer

Widely used cancer drug bevacizumab can lead to proteinuria, kidney damage: Study

UAB researchers win grant to study metastasis of dead cancer cells

Event guide: 7th Allogeneic Cell Therapies Summit eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News